According to a peer reviewed study published in the Journal of Allergy and Clinical Immunology, the Covid-19 vaccine was less effective at keeping people out of hospital than the Pfizer-BioNTech shot.
The risk of being hospitalized with severe Covid-19 after vaccination was five times higher in people who had received the J&J vaccine compared to the Pfizer-BioNTech shot, according to a study.
The researchers found that Pfizer's vaccine was effective at preventing hospitalization with severe Covid, compared to the J&J vaccine.
The study is the largest to evaluate the effectiveness of the J&J vaccine in the general population to date and includes almost the entire population of France who received the shot.
The researchers said they couldn't completely exclude factors such as age, sex, vaccination day and area of residence from being a factor in the difference.
The researchers said that the technology used in Moderna and Pfizer shots is already recommended in France and the U.S.
A single J&J shot was shown to be 85% effective in clinical trials. The figure dropped to around 70% in later studies. J&J is the worst performing vaccine in the US, and the CDC recommends everyone get a booster shot of either Pfizer or Moderna. Data overwhelmingly shows that the J&J vaccine is still more dangerous to be unvaccinated than any other vaccine.
Is J&J fully protected? The recipients of the least-used U.S. vaccine are often left in the dark as communications focus on more widely used Pfizer and Moderna vaccines. One dose of J&J or two of Moderna and Pfizer are counted by the CDC. Though people who have had the J&J shot and another booster will be considered fully vaccination and up to date, data still shows that the vaccine still offers higher levels of protection, making it unclear whether J&J recipients will need a third shot. Over the course of the Pandemic, the use of the vaccine has dropped in favor of mRNA shots. Official guidelines don't address the matter.
17 million dollars. According to CDC data, how many people have received the J&J vaccine in the U.S. More than 123 million have received two doses of Pfizer's shot.
Despite the need in developing countries, Johnson has paused vaccine production.
Live updates on the coronaviruses.